Review proposes a link between CCT/TRiC chaperonin activity and therapy-induced senescence in glioblastoma
This review of glioblastoma proposes that the chaperonin CCT/TRiC helps maintain glioma stem cells and may be mechanistically linked to therapy-induced senescence; inhibiting it is proposed as a possible therapeutic approach, not a validated treatment. [1]
Automatic summary · not editorially reviewed
The key findings
The review reports growing evidence that standard glioblastoma therapies drive many cells into therapy-induced senescence, whose persistence can fuel recurrence. [1]
The authors propose that CCT/TRiC is probably involved in maintaining glioma stem cell proteostasis via several signaling pathways. [1]
The authors propose that CCT/TRiC inhibition could impair macroautophagy by disrupting mTOR signaling, and outline possible combination strategies. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Glioblastoma multiforme cells and glioma stem cells, as discussed in a review
- Summary based on
- Study abstract
- Original publication
- August 20, 2026
Glioblastoma therapy and therapy-induced senescence
Glioblastoma multiforme is described as the most lethal primary brain tumor despite maximal resection, radiotherapy and temozolomide. The authors report growing evidence that standard therapies drive many glioblastoma cells into therapy-induced senescence, marked by permanent proliferation arrest, high metabolic activity and the senescence-associated secretory phenotype (SASP). Senescent cells may initially limit growth, but their persistence can fuel recurrence by altering the microenvironment and driving immunosuppression and stem-like traits.
Supporting source [1]
Proposed CCT/TRiC role in glioma stem cells
Glioblastoma is described as chaperone dependent, relying on proteostasis networks for rapid growth, invasion and treatment resistance. CCT/TRiC is an ATP-dependent complex of eight subunits (CCT1–CCT8) essential for folding actin and tubulin and for maturing multiple oncogenic clients. The authors review findings on CCT/TRiC subunit dysregulation in glioblastoma and propose that CCT/TRiC is probably involved in maintaining glioma stem cell proteostasis by modulating EGFR, TGF-β, mTOR, Wnt/β-catenin and Notch pathways, thereby supporting survival, self-renewal and invasiveness.
Supporting source [1]
Proposed inhibition, autophagy and therapeutic strategies
The review proposes a mechanistic link between chaperonin activity and senescence, integrating p53/p21 and p16INK4a/Rb signaling, EGFR-driven survival, hypoxia/HIF-mediated metabolic reprogramming and immune infiltration in high-SASP tumors. The authors also propose that CCT/TRiC inhibition could impair macroautophagy by disrupting mTOR signaling—both crucial for sustaining senescence and SASP—thereby compromising proteostasis and autophagic flux. Finally, they outline possible therapeutic strategies based on this axis, including novel combinations of senolytics, immunotherapy potentiators and CCT/TRiC-targeted agents to prevent SASP-driven progression and relapse. These are proposals, not validated treatments.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The mechanistic links and therapeutic strategies are proposed by the authors, not established treatments, and no clinical outcomes are reported in the abstract.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Augello MA, Wnuk M, Caruso Bavisotto C, Cappello F, Scalia F. · europepmc.org · August 20, 2026